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S272 Poster Session Ineutrophil content (r5 -0.20, p\0.0001).Multiple regression analysis
demonstrated that collection to freeze interval (p5 0.006), neutrophil
content (p\ 0.0001) and allogeneic donors (p\ 0.001) significantly
affected viable CD34 recovery, but NCC did not (p5 0.14).
Of the 35 cryopreserved allogeneic products, 11 have been infused
with no significant difference in terms of engraftment of neutrophils
(median 18; range 11-31) and platelets (median 27; range 14-58),
when compared to infusion of 179 fresh allogeneic products (neutro-
phils: median 17, range 4-55, p 5 0.9; platelets: median 19, range1-
101, p 5 0.2).
This data indicates that the lower post-thawviableCD34 recovery in
PBSCmaybedue to intrinsicpropertiesof allogeneicdonor inaddition
to the neutrophil content and prolonged storage periods prior to cryo-
preservation. Post thawanalysis of viableCD34+ content is recommen-
ded to ensure sufficient viable CD34+ to facilitate engraftment.
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CREATION OF A SEGMENT-BASED ALDEHYDE DEHYDROGENASE ASSAY
AS A BIOMARKER FOR UMBILICAL CORD BLOOD POTENCY
Shoulars, K.1, Gentry, T.2, Page, K.1, Balber, A.2, Kurtzberg, J.1 1Duke
University Medical Center, Durham, NC; 2Aldagen Inc, Durham, NC
Banked, unrelated umbilical cord blood units (CBU) provide an op-
tion for transplantation for patients lacking matched donors. Current
methods for selecting a suitableCBU for transplantation include exam-
ining the human leukocyte antigen (HLA) matching, total nucleated
cell (TNC) count, and, in some situations, viable CD34 counts on
the unit prior to cryopreservation. However, 20% of patients experi-
ence primary graft failure following UCB transplantation (UCBT),
suggesting a better assay to assess potency on a thawed CBU prior to
the release from the cord blood bank is needed. Preliminary clinical
studies demonstrated that neutrophil and platelet engraftment as well
asoverall survival canbepredictedwithpost-thawcolony formingunits
(CFU). The usefulness of post-thawCFU as a potency assay is limited
both by time (14 days) and variability. However, CFUs in fresh cord
blood are highly correlated with the number of hematopoietic progen-
itor cells expressing high levels of the enzyme aldehyde dehydrogenase
(ALDHbr cells). Retrospective studies of transplanted CBUs indicated
that engraftment success was accurately predicted by the number of
ALDHbr cells infused per kilogram. Therefore, we developed an
ALDHbr assay for segments attached to CBUs to measure potency
for UCBT on segments used for HLA confirmatory typing (CT).
Wemeasured CFUs and flow cytometric analysis on 334 segments re-
quested for CT. Each segment was thawed and blood was spotted on
a FTA card for CT. The remaining blood was washed with 5% dex-
tran/albumin to remove the DMSO. Following removal of 100,000
white blood cells for CFU, the content of ALDHbr [Aldecount],
CD34+, CD45+, glycophorin A+ and viable (7-AAD+) cells was mea-
sured by flow. Comparisons of the data from the CT segments show
thatALDHbr correlateswellwithCFUs (R25 0.809), at a ratio approx-
imately 4 ALDHbr cells per 1 CFU. In contrast, CFU and ALDHbr
counts do not correlate well with viableCD45+ or viable CD34+ count.
Of the 334 units assayed, 82 have been administered to patients.
Several graft parameters of potential use in measuring potency of
a CBU can be measured prospectively on a segment at the time of
CT and can provide information for unit selection. Using unit values
calculated from the CT segment, we will compare clinical outcomes
to the graft parameters in order to determine which provide predic-
tive information concerning neutrophil and platelet engraftment and
overall survival after UCBT.SUPPORTIVE CARE
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COLLECTION OF G-CSF-MOBILIZED GRANULOCYTES FROM RELATED
DONORS TO SUPPORT HEMATOPOIETIC STEM CELL TRANSPLANT RE-
CIPIENTS AT HIGH RISK OF INFECTION IS SAFE AND FEASIBLE
Tewari, P.1, Allison, J.1, Waters-Pick, B.2, Cash, J.V.1, Kurtzberg, J.1,
Prasad, V.K.1 1Duke University Medical Center, Durham, NC; 2Duke
University Medical Center, Durham, NC
Background: Granulocyte transfusions may be useful for patients
undergoing hematopoietic stem cell transplantation (HSCT) at
high risk for the development of life-threatening infections during
the neutropenic period. However, their usefulness depends on feasi-bility and safety of repeated collections of GCSFmobilized granulo-
cytes from related donors.
Methods: A total of 1,536 leucophereses to collect granulocytes
from 148 GCSF-mobilized related donors were performed between
1999 and 2009 at Duke to treat 139 HSCT recipients. Donors were
screened by a rigourous health history questionnaire and by blood
tests for a number of infectious diseases. Central venous line
(CVL) placement was performed under sedation or anesthesia. Sub-
cutaneous G-CSF (10mcg/kg) was given the night before pheresis,
twice weekly. Each collection was divided into 3 aliquots and infused
daily to provide dosing for 6 days per week. Donors received oral
iron, vitaminK, and calcium supplements. They were carefully mon-
itored with regular clinical and laboratory tests for any adverse ef-
fects. All products were regularly assayed for total nucleated cell
counts (TNC), viability and sterility.
Results: Of 148 donors, 74 were male and 62 CMV seropositive.
Their median age was 36.8 years (range: 17-58) and median weight
was 79.3 kg (50.9 - 183.5). Donors were fathers (n 5 72), mothers
(n 5 57), siblings (n 5 8), or other relatives (n 5 11). Past medical
history was negative in all but 13 donors (asthma, n 5 5; hyperten-
sion, n 5 3; diabetes, n 5 1; others, n 5 4). Donors underwent
a median of 8 phereses (range, 1-71) over a median of 25 days (range,
1-266). Complications included pruritis (n 5 8), fever (n 5 3), bac-
teremia (n5 15), CVL tract infection (n5 1), exit site related minor
bleeding (n5 3), local discharge (n5 7), and erythema (n5 8). Five
required 2 or more CVLs. Laboratory abnormalities included LFT
elevation (n5 1), PT. 16 sec (n5 2), and fibrinogen\100 mg/dL
(n 5 1). Between the first and the last pheresis, the median drop in
Hemoglobin was 2.5 gm/dL (range, 0-6.8) and the drop in serum al-
bumin was 0.6 gm/dL (range, 2-2.2). Ten of 1536 granulocyte prod-
ucts were contaminated with bacteria. Pheresis was stopped for all
fevers and positive line cultures.
Conclusions:When performed at an experienced center using well
defined guidelines and good supportive care, granulocyte collection
from family donors following GCSF stimulation is safe and feasible.327
ERYTHROPOIETIN-ASSISTED PHLEBOTOMY IN STEM CELL TRANSPLANT
PATIENTS WITH IRON OVERLOAD
Schwalier, E., Laws, A., Osswald, M.B. San Antonio Military Medical
Center
Stem cell transplantation often necessitates repeated transfusions
raising the risk of secondary hemochromatosis. Erythropoietin-as-
sisted phlebotomy (EAP) is a potential treatment to alleviate iron
overload in these patients.
Methods: We carried out a retrospective review of 372 stem cell
transplants at our hospital from 2000 to 2008.We evaluated themax-
imum ferritin level for each patient and used a level of 1,000 ug/mL
to identify patients at increased risk for complications of iron over-
load. 65 patients had ferritin levels\1,000ug/mL and served as con-
trols. Groups were further subdivided into those who received
therapeutic EAP and those who did not. Records were also reviewed
for transplant related infections.
Results: Among the 56 patients with ferritin levels over 1,000ug/
mL, the average ferritin level was 2,965ug/mL. These patients re-
ceived an average of 26.6 units of transfused PRBCs during their
transplant course. Ten of these patients underwent EAP of 500cc
of blood approximately every two weeks to decrease their ferritin
level. The non-phlebotomized group had an increased rate of infec-
tions and trended toward a higher mortality. The non-phlebotomy,
hyperferritinemia group had the highest rates of infection within our
three groups at both three and six months (p\0.004 and p\0.008)
but not at 1 year (p\ 0.086). There was no significant difference in
infection rates in the EAP group and the controls at either 3 or 6
months. (p\ 0.17, p\ 0.107) Mortality differences between the
two main groups (ferritin . 1,000ng/ml and ferritin\ 1,000 ng/
ml) were significant at both six months and one year (p\ 0.0004
and p\ 0.005 respectively). There was also a significant difference
between the hyperferritinemia group who did not receive EAP and
controls at both six months and one year (p \ 0.00002 and p \
0.0004 respectively). Two-tailed Fishers exact test showed that the
mortality rate between the two subsets in the hyperferritinemia
group was significant at six months (p 5 0.009 two sided; p 5
Poster Session I S2730.005 one sided) but not at 1 year (p 5 0.34, two-sided). There was
no significant difference in mortality rates between the EAP group
and the control group.
Conclusions: Multiple transfusions raise the risk of secondary he-
mochromatosis, a risk factor for infections and increased mortality.
Erythropoietin-assisted phlebotomy is a treatment to prevent the
complications of iron overload in HSCT patients.328
SAFETY AND IMMUNOGENICITY OF HEAT-TREATED ZOSTER VACCINE
(ZVHT) IN ADULTS WITH ALLOGENEIC OR AUTOLOGOUS HEMATOPOI-
ETIC STEM-CELL TRANSPLANTS (HCT)
Winston, D.1, Mullane, K.2, Boeckh, M.3, Zhao, Y.4, Fernsler, D.4,
Manoff, S.4, Annunziato, P.4 1University of California - Los Angeles;
2University of Chicago; 3Fred Hutchinson Cancer Research Center;
4Merck & Co., Inc
Background: Herpes zoster incidence is higher in patients with
a hematopoietic stem cell transplant [HCT] (200 cases/1000 per-
son-years) than in the general population (3-5 cases/1000 per-
son-years). A heat-treated zoster vaccine [ZVHT] was assessed in
adults with allogeneic or autologous HCT.
Methods: Randomized, double-blind, placebo-controlled, multi-
center Phase I study of a 4-dose ZVHT regimen (1 dose pre-HCT;
3 doses post-HCT, each 30 days apart) in adults $ 18 years with
autologous (n 5 50) or allogeneic (n 5 50) HCT. In each group,
40 received ZVHT and 10 placebo (Pbo). Bloodwas collected at base-
line & 28 days after each dose to measure (1) VZV antibody con-
centrations by glycoprotein enzyme-linked immunosorbent assay
(gpELISA), and (2) varicella zoster virus (VZV) T-cell responses
by interferon-gamma enzyme-linked immunospot (IFN-g ELI-
SPOT) assay. All vaccinated patients were evaluated for adverse
events (AEs) through day 28 postdose 4. Immunogenicity analyses
for both HCT groups were exploratory (no pre-specified hypothe-
ses).
Results: ZVHT safety profile was similar to placebo. Injection-site
adverse events (AEs) occurred in 15% of the ZVHT group and
10% of the Pbo group. There were no reported vaccine-related
serious AEs. No patients discontinued due to vaccine-related AEs.
Herpes zoster (PCR positive) occurred in 1 ZVHT and 1 placebo pa-
tient (both autologous HCT patients). There were also 2 patients in
the ZVHT group that had suspected HZ not confirmed by PCR (1 inTable 1. Immunogenicity Results Summary
Allogeneic HCT Autologous HCT
ZVHT Placebo ZVHT Placebo
[N540] [N510] [N540] [N510]
[n] Response
(90%CI)
[n] Response
(90%CI)
[n] Response
(90%CI)
[n] Response
(90%CI)
Day 1 (baseline)
GMC [28] 13.7 (6.6,28.4) [7] 4 (0.7,22.2) [31] 9.1 (5.2,15.9) [7] 8.6 (2,8,26.1)
Postdose 1
GMC [29] 2.2 (1.1,4.2) [9] 1.1 (0.5,5.5) [24] 10.8 (5.3,22.3) [7] 4.3 (1.7,10.9)
GMFR [20] 0.1 (0.0,0.3) [7] 0.2 (0.1,1.0) [20] 0.4 (0.2,0.9) [7] 0.5 (0.1,2.1)
Postdose 2
GMC [27] 2.6 (1.5,4.4) [8] 1.1 (0.7,1.7) [25] 12.6 (5.6,28.4) [5] 4.8 (0.5,50.0)
GMFR [20] 0.2 (0.2,0.4) [6] 0.4 (0.1,1.8) [18] 0.6 (0.3,1.2) [3] 1.2 (0.0,287.4)
Postdose 3
GMC [22] 2.1 (1.0,4.3) [7] 0.9 (0.6,1.4) [27] 63.3 (33.0,121.3) [5] 2.0 (0.4,9.6)
GMFR [14] 0.1 (0.0,0.5) [6] 0.3 (0.1,1.8) [21] 4.5 (1.7,11.7) [3] 0.1 (0.0,2.5)
Postdose 4
GMC [26] 2.7 (1.5,4.9) [5] 0.5 (0.5,0.5) [24] 92.2 (47.0,180.9) [5] 4.9 (0.8,30.5)
GMFR [17] 0.2 (0.1,0.5) [4] 0.2 (0.0,7.8) [19] 7.6 (2.7,21.7) [4] 0.5 (0.1, 4.7)
N5number of patients vaccinated.
n5number of patients included in analysis.
GMC5geometric mean count.
GMFR5geometric mean fold rise from Day1 (baseline).eachHCT group). No ZVHT recipient had a rash that was PCR pos-
itive for the vaccine strain of VZV.
At baseline, the VZV-specific gpELISA geometric mean titer
(GMT) was 152 (90% CI: 107, 216) in allogenic HCT patients
and 214 (90%CI: 147, 311) in autologous HCT patients. Both mea-
sures decreased Postdose 4: 139 (90% CI: 103, 189) and 196 (90%
CI: 126, 305), respectively. VZV-IFN- g responses are summarized
in the table below.
Conclusion: 4 doses of ZVHT had an acceptable safety profile in pa-
tients undergoingHCT. Significant T-cell responses were elicited in
patients undergoing autologous HCT, but not in patients undergo-
ing allogeneic HCT.
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INCREASED RESTING ENERGY EXPENDITURE IS ASSOCIATED WITH
FAILURE TO THRIVE IN SEVERE COMBINED IMMUNODEFICIENCY
Makhija, M., Barron, M.A., Hagen, L.E.M., Pencharz, P.,
Grunebaum, E., Roifman, C. The Hospital for Sick Children, Toronto,
ON, Canada
Introduction: Patients with Severe Combined Immunodeficiency
(SCID) often suffer from failure to thrive (FTT) caused by chronic
infections, poor energy intake and/or malabsorption. Increased rest-
ing energy expenditure (REE)might also contribute to FTT in these
patients as it does in patients with other immune deficient states in-
cluding HIV and malignancy.
Objectives:Our objectives were to measure REE (MREE) and de-
termine if increased REE (hypermetabolism) is associated with
FTT in SCID patients at diagnosis prior to bone marrow trans-
plantation.
Study Design: REE was measured by indirect calorimetry in 26 pa-
tients with SCID, before BMT conditioning, at a single transplant
center. Predicted REE (PREE) was determined byWHO standards.
MREE. 110% of PREE was classified as hypermetabolism. Other
data collected at diagnosis included FTT status, infectious history,
genotype, phenotype and the feeding methods used.
Results: Fifteen of 26 (57.7%) patients were FTT and 18/26 (69.2%)
were hypermetabolic. Hypermetabolism occurred in 14/15 (93%) pa-
tients with FTT, while only 4/11 (36%) patients without FTThad hy-
permetabolism (P5 0.003).Therewas a significant difference between
the MREE (455 6 169 kcal) and the PREE (333 6 106 kcal) (p\
0.0001). Hypermetabolism was significantly more common in those
between the ages of 3-12 months. Logistic regression was performed
to determine the probability of FTT using the MREE expressed as
a percentage of the PREE for age and gender, adjusted for diarrhea
and pneumonia. An increased probability of FTT was found, if hyper-
metabolism was present, independent of diarrhea and pneumonia.
Eleven of 17 (65%) patients required nasogastric feeding and/or paren-
teral nutrition to meet their energy needs.
Conclusions: Hypermetabolism is common in patients with SCID
in the pre-BMT period and may contribute to the development of
FTT. The hypermetabolism in these patients may necessitate inten-
sive nutrition support.
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EXPERIENCE WITH CMX001, A NOVEL ANTIVIRAL DRUG, FOR CYTO-
MEGALOVIRUS INFECTIONS IN STEM CELL TRANSPLANT PATIENTS
Papanicolau, G.1, Kurtzberg, J.2, Westervelt, P.3, Gea-Banacloche, J.4,
Warlick, E.5, Lanier, R.6, Anderson, M.6, Painter, W.6 1Memorial Sloan
Kettering Cancer Center, New York, NY; 2Duke UniversityMedical Cen-
ter, Durham, NC; 3Washington University School of Medicine, St. Louis,
MO; 4National Cancer Institute, Bethesda, MD; 5University of Minne-
sota, Minneapolis, MN; 6Chimerix, Inc., Durham, NC
Cytomegalovirus (CMV) infections are associated with signifi-
cant morbidity and mortality in the stem cell transplant setting.
CMX001, a lipid conjugate of cidofovir is administered orally
and circulates as the lipid conjugate in plasma; it is efficiently taken
up by target cells and high concentrations of the active antiviral are
achieved intracellularly. We describe the first clinical experiences
in stem cell transplant patients infected with CMV who received
CMX001. The patients had history of AML (3 patients), refractory
lymphoma, multiple myeloma, and severe aplastic anemia, and
sickle cell anemia. Six of the seven patients had received SCT
and the seventh awaited SCT. Treatment with CMX001 was
